[go: up one dir, main page]

MX2017012824A - Tratamiento de cáncer de pulmón con inhibidores de glutaminasa. - Google Patents

Tratamiento de cáncer de pulmón con inhibidores de glutaminasa.

Info

Publication number
MX2017012824A
MX2017012824A MX2017012824A MX2017012824A MX2017012824A MX 2017012824 A MX2017012824 A MX 2017012824A MX 2017012824 A MX2017012824 A MX 2017012824A MX 2017012824 A MX2017012824 A MX 2017012824A MX 2017012824 A MX2017012824 A MX 2017012824A
Authority
MX
Mexico
Prior art keywords
lung cancer
glutaminase inhibitors
cancer treatment
glutaminase
inhibitors
Prior art date
Application number
MX2017012824A
Other languages
English (en)
Other versions
MX383034B (es
Inventor
Zhang Dong
Parlati Francesco
G Works Melissa
L M Rodriguez Mirna
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of MX2017012824A publication Critical patent/MX2017012824A/es
Publication of MX383034B publication Critical patent/MX383034B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a métodos para tratar cáncer de pulmón usando inhibidores de glutaminasa. En particular, los resultados demuestran que los cánceres de pulmón caracterizados por una mutación EGFR o KRAS son tratados por inhibidores de glutaminasa.
MX2017012824A 2015-04-06 2016-04-06 Tratamiento de cáncer de pulmón con inhibidores de glutaminasa. MX383034B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562143494P 2015-04-06 2015-04-06
US201562149489P 2015-04-17 2015-04-17
PCT/US2016/026127 WO2016164401A1 (en) 2015-04-06 2016-04-06 Treatment of lung cancer with inhibitors of glutaminase

Publications (2)

Publication Number Publication Date
MX2017012824A true MX2017012824A (es) 2018-05-15
MX383034B MX383034B (es) 2025-03-13

Family

ID=57015711

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012824A MX383034B (es) 2015-04-06 2016-04-06 Tratamiento de cáncer de pulmón con inhibidores de glutaminasa.

Country Status (13)

Country Link
US (1) US10441587B2 (es)
EP (1) EP3280415A4 (es)
JP (2) JP6944377B2 (es)
KR (1) KR20170132333A (es)
CN (1) CN107949387B (es)
AU (1) AU2016246521B2 (es)
BR (1) BR112017021312A2 (es)
CA (1) CA2981762A1 (es)
EA (1) EA035354B1 (es)
IL (1) IL254876A0 (es)
MX (1) MX383034B (es)
SG (1) SG11201708153XA (es)
WO (1) WO2016164401A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
LT2920168T (lt) 2012-11-16 2021-10-25 Calithera Biosciences, Inc. Heterociklinis gliutaminazės inhibitorius
GEP20186879B (en) 2014-04-30 2018-07-10 Pfizer Cycloalkyl-linked diheterocycle derivatives
SG11201700816YA (en) 2014-08-07 2017-02-27 Calithera Biosciences Inc Crystal forms of glutaminase inhibitors
CN108601767A (zh) 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
CN109982703A (zh) * 2016-08-25 2019-07-05 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法
JP2019526560A (ja) 2016-08-25 2019-09-19 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤との併用療法
CA3055562A1 (en) * 2017-03-10 2018-09-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
JP7188936B2 (ja) * 2018-08-21 2022-12-13 国立大学法人富山大学 抗炎症剤
JP7156856B2 (ja) * 2018-08-21 2022-10-19 国立大学法人富山大学 抗肥満剤
WO2021076814A1 (en) * 2019-10-15 2021-04-22 Cornell University Methods of inhibiting liver-type glutaminase, gls2
US20240082158A1 (en) * 2020-05-21 2024-03-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for administering a yap1/wwrt1 inhibiting composition and a gls1 inhibiting composition
CN111514460B (zh) * 2020-05-22 2021-12-14 西安交通大学 大气压冷等离子体在抑制谷氨酰胺酶活性方面的用途及酶抑制剂
CN113956233B (zh) * 2021-10-22 2023-06-06 南方医科大学 一种酰胺类化合物或其药学上可接受的盐及其制备方法和应用
US20250288577A1 (en) * 2022-04-29 2025-09-18 Cornell University Methods of treating a virus infection and methods of inhibiting viral replication

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1019519A (en) 1911-07-11 1912-03-05 Oscar Martin Polin Apparatus for making backing for teeth.
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
US20040198716A1 (en) 2001-02-05 2004-10-07 Dorit Arad Cysteine protease inhimbitors
ES2367311T3 (es) 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
WO2009104696A1 (ja) 2008-02-19 2009-08-27 株式会社アーネストメディスン 身体機能の回復に有用な経口又は経腸組成物
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US10064885B2 (en) 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
MX2013005434A (es) 2010-11-18 2013-09-26 Deuteria Pharmaceuticals Inc 3´ - deutero - polidomida.
CN103030597B (zh) * 2011-09-30 2014-10-01 南昌滨西科技有限公司 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途
SI2782570T1 (sl) 2011-11-21 2020-02-28 Calithera Biosciences Inc. Heterociklični inhibitorji glutaminaze
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
US10138479B2 (en) * 2012-05-24 2018-11-27 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
US9694015B2 (en) 2012-09-10 2017-07-04 Celgene Corporation Methods for the treatment of locally advanced breast cancer
ES2690829T3 (es) 2012-09-17 2018-11-22 Agios Pharmaceuticals, Inc. Uso de e-cadherina y vimentina para la selección de pacientes que responden al tratamiento
LT2920168T (lt) 2012-11-16 2021-10-25 Calithera Biosciences, Inc. Heterociklinis gliutaminazės inhibitorius
JP6333280B2 (ja) 2012-11-21 2018-05-30 アジオス ファーマシューティカルズ， インコーポレイテッド グルタミナーゼ阻害剤およびその使用方法
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
SG11201504184PA (en) * 2012-12-03 2015-06-29 Calithera Biosciences Inc Treatment of cancer with heterocyclic inhibitors of glutaminase
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
EP3116872A4 (en) 2014-03-14 2017-08-30 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US10221459B2 (en) 2014-05-13 2019-03-05 Case Western Reserve University Compositions and methods of treating cancer harboring PIKC3A mutations
CN107027291B (zh) 2014-06-13 2020-10-30 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法
WO2016004418A1 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Glutaminase inhibitor therapy
WO2016014890A1 (en) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
SG11201700816YA (en) 2014-08-07 2017-02-27 Calithera Biosciences Inc Crystal forms of glutaminase inhibitors
US10245254B2 (en) 2014-10-03 2019-04-02 University of Pittsburgh—of the Commonwealth System of Higher Education Glutaminase inhibitors
US10517844B2 (en) 2014-11-13 2019-12-31 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
EA037152B1 (ru) * 2015-03-30 2021-02-11 Калитера Байосайенсиз, Инк. Способ лечения рака
WO2018039442A1 (en) 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Treatment of cancer with inhibitors of glutaminase
JP2019526560A (ja) 2016-08-25 2019-09-19 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤との併用療法
CN109982703A (zh) 2016-08-25 2019-07-05 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法

Also Published As

Publication number Publication date
CA2981762A1 (en) 2016-10-13
KR20170132333A (ko) 2017-12-01
MX383034B (es) 2025-03-13
CN107949387B (zh) 2021-08-13
AU2016246521A8 (en) 2019-08-15
EA201792227A1 (ru) 2018-11-30
JP6944377B2 (ja) 2021-10-06
US20160287585A1 (en) 2016-10-06
EP3280415A4 (en) 2018-12-26
EP3280415A1 (en) 2018-02-14
JP2018510884A (ja) 2018-04-19
CN107949387A (zh) 2018-04-20
WO2016164401A1 (en) 2016-10-13
JP2021102662A (ja) 2021-07-15
HK1254349A1 (zh) 2019-07-19
AU2016246521B2 (en) 2020-07-09
US10441587B2 (en) 2019-10-15
SG11201708153XA (en) 2017-11-29
BR112017021312A2 (pt) 2018-06-26
AU2016246521A1 (en) 2017-11-02
EA035354B1 (ru) 2020-06-01
IL254876A0 (en) 2017-12-31
WO2016164401A8 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
MX383034B (es) Tratamiento de cáncer de pulmón con inhibidores de glutaminasa.
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
MX392368B (es) Composiciones y metodos para el tratamiento del cancer
EA201992781A1 (ru) Ингибиторы g12c kras и способы их применения
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
PH12019500668B1 (en) Anti-lag-3 antibodies and compositions
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2020006297A (es) Variantes de cd19.
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
EA201790802A1 (ru) Соединения против tnf
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
EA201692472A1 (ru) Соединения для лечения рака мозга
MX379621B (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX382996B (es) Inhibidores de pcna
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MX379271B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
TW201613587A (en) Medical treatments based on anamorelin
EA201890884A1 (ru) Способ и композиции для нежелательных и аномальных мышечных сокращений
MX390320B (es) Farmaco de combinacion.
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
GB2569488A (en) PD-1 specific aptamers